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Aging is the major risk factor for both the development of chronic diseases and loss of functional 
capacity. Geroscience provides links among the biology of aging, the biology of disease, and the 
physiology of frailty, three fields where enormous progress has been made in the last few decades. 
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other side of this relationship, which is the contribution of disease to aging, has been less explored 
at the molecular/cellular level. Indeed, the role of childhood or early adulthood exposure to chronic 
disease and/or treatment on accelerating aging phenotypes is wel known in epidemiology, but the 
biological basis is poorly understood. A recent summit co-organized by the National Institutes of 
Health GeroScience Interest Group (GSIG) and the New York Academy of Sciences (NYAS) explored 
these relationships, using three chronic diseases as examples: cancer, HIV/AIDS, and diabetes. The 
epidemiological literature clearly indicates that early exposure to any of these diseases and/or their 
treatments results in an acceleration of the appearance of aging phenotypes, including loss of 
functional capacity and accelerated appearance of clinical symptoms of aging-related diseases not 
obviously related to the earlier event. The discussions at the summit focused on the molecular and 
cellular relationships between each of these diseases and the recently defined molecular and cellular 
pillars of aging. Two major conclusions from the meeting include the desire to refine an operational 
definition of aging and to concomitantly develop biomarkers of aging, in order to move from 
chronological to physiological age. The discussion also opened a dialogue on the possibility of 
improving late-life outcomes in patients affected by chronic disease by including age-delaying 
modalities along with the standard care for the disease in question.  
 




Aging is often accompanied by multiple chronic diseases, a state called multimorbidity.1 It is widely 
recognized that multimorbidity is the result of the functional decline that occurs in all organisms as a 
function of age. This leads to an enhanced susceptibility to those diseases for which an individual is 
most predisposed, based on his/her genes and environment.2 Consequently, aging is acknowledged 
as the major risk factor for most chronic diseases and disabilities. Aging is not itself a disease but 
rather a natural process, and impressive progress has been made recently in understanding the 
biology, genetics, and physiology of aging. Furthermore, in a variety of species, the rate of aging is 
subject to modulation by several behavioral, genetic and––more recently––pharmacological 
interventions.3 Interestingly, interventions that can significantly extend life span most often succeed 
in also improving at least some aspects of health at older ages. These may be viewed as slowing the 
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any single intervention will improve all aspects of aging physiology, the search continues to find 
interventions or combinations of interventions where the benefits will outcompete the risks.4 
This progress in understanding and manipulating the rate of aging has made possible the 
emergence of geroscience, a field that aims at exploring the molecular and cellular elements that lie 
at the intersections among basic aging biology, aging physiology, and chronic disease.6 Indeed, the 
geroscience hypothesis states that, by reducing the rate of aging, it should be possible to delay or 
slow down the appearance and progression of most age-related chronic diseases, in parallel. At the 
onset, the goal of geroscience was to try to unravel the biological basis for why aging is the major 
risk factor for disease. However, health is more than just the absence of disease, and an exclusive 
focus on diseases might not be the ideal way to proceed. In fact, it can be argued that focusing most 
of the resources for biomedical research on those diseases that represent major killers might not be 
desirable if other aspects of health and well-being are neglected. In that context, it is important to 
acknowledge that aging is also a major risk factor for the loss in functionality that leads to an 
inability to perform the activities of daily living, with a corresponding decrement in quality of life. So, 
realizing that aging is the main driver for the general loss of functional capacity and the development 
of aging phenotypes, even in the absence of overt disease, the field has been moving towards 
focusing more on health, whereby aging is not solely a major risk factor for disease but also a major 
risk factor for loss of health in a broader context. In addition, researchers in the basic biology of 
aging who are working on health span are coming to appreciate what gerontologists recognize in 
their clinical practice: good health is viewed differently at different ages, and this presents another 
challenge for geroscience. 
Research in aging biology has allowed the definition of a series of so-called “pillars of aging,” 
a handful of molecular and cellular processes whose dysfunction as a result of aging is thought to 
drive the age-related functional loss and appearance of aging phenotypes.7–9 The relevance of each 
of these pillars to disease susceptibility was the topic of the first Geroscience Summit, held at the 
National Institutes of Health (NIH) Campus in 2013 and titled “Advances in geroscience: Impact on 
Healthspan and Chronic Disease.” The outcomes of that meeting have been published.10 When the 
time came to organize a second geroscience summit, a different tack was chosen: instead of focusing 
on aging as a major risk factor for disease, a decision was made to address the opposite side of the 
coin: how do exposures to early disease (or their treatments) affect the pillars of aging, thus paving 
the way to accelerated development of aging phenotypes and chronic disease? Asking this question 
was reasonable given a substantial volume of epidemiological data, and the question still fits within 
the conceptual frame of the pillars of aging, since the pillars do include  an “other biology” category. 
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might be known at this time, and there are likely to be additional, as-yet poorly understood 
modifiers. On the basis of the epidemiological data, exposure to chronic or life-threatening diseases 
in early or middle life could represent one such as-yet poorly defined additional pillar.  
As a result, and in conjunction with the New York Academy of Sciences, the trans-NIH 
GeroScience Interest Group (GSIG) organized a second geroscience summit, held in New York City in 
April 2016, titled “Disease Drivers of Aging.” In order to focus the discussion, only three disease 
clusters were chosen as test cases: cancer, HIV/AIDS, and diabetes. It is a well-known 
epidemiological fact that cancer or HIV/AIDS survivors are affected by premature frailty and early 
appearance of a number of chronic diseases that normally affect older adults. Childhood cancers 
represent a minor but emotionally devastating subset of all cancers.11–14 Because life-saving cancer 
therapy has been available for decades, many childhood cancer patients are now middle-aged or 
older, and the epidemiological data clearly indicate adverse effects later in life, often in tissues and 
systems not obviously affected by the initial insult or targeted by the initial treatment. Similarly, 
development of effective therapies against HIV/AIDS means that patients are surviving in large 
numbers, and many of them are now reaching older ages, having been exposed to the disease 
earlier in life, and to long-term treatments, a situation that differs from the example of cancer.13 The 
case of diabetes is slightly different: while sequelae of diabetes can indeed be lethal, palliative 
methods have been available for long enough that we do not regularly refer to these patients as 
survivors, yet diabetes has long been proposed to represent an accelerated aging phenotype.15 
Indeed, many of the metabolic changes observed in diabetes mimic observations made in the aged, 
though in some cases with differences on the exact physiopathology.16  
While the epidemiological data for apparent acceleration of aging phenotypes is compelling 
in all three cases, not much is known about the molecular and cellular drivers of this effect. The goal 
of the Second Geroscience Summit was therefore to address this issue: how do these diseases 
and/or their treatments affect the known pillars of aging? And a related question: are these effects 
transiently present only while the disease condition is present, or do the diseases/treatments leave a 
permanent imprint in the aging pillars, which could explain molecularly why affected individuals are 
handicapped later in life. A discussion of major issues in each of these domains is presented in this 
report.  
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The majority of cancer diagnoses and cancer deaths occur in individuals age 65 and older. Given the 
association between cancer and aging and the aging of the U.S. population, we are in the midst of a 
substantial rise in the number of new cases of cancer diagnosed in the United States. There will be a 
projected 67% increase in cancer incidence in adults age 65 and older between 2010 to 2030.17 
While cancer was once a deadly disease, improvements in early diagnosis and treatment are 
resulting in a substantial growth in the number of cancer survivors, estimated at 8 million presently 
in the United States and growing to 11 million by 2020.18 Hence, the impact of both cancer and its 
treatment on the aging process is an area of increasing importance.  
There are several reasons why cancer therapies may affect the aging process. First, the 
mechanism of action of cancer therapeutics is primarily aimed at targeting one or more of the pillars 
of aging, such as genomic instability, epigenetic alterations, and cellular senescence, with the intent 
to target the tumor; however, the host is likely to sustain a bystander effect. Second, unlike most 
therapeutic approaches, the doses of the systemic therapies against cancer are often determined by 
the maximum tolerated dose (the highest dose of the cancer therapeutic that can be delivered to 
target the tumor without the patient experiencing extreme side effects) rather than the minimum 
effective dose. Third, and most important for this discussion, the studies evaluating the efficacy and 
toxicity of cancer therapeutics are often performed in younger adults, rather than in older adults 
who represent the majority of those with cancer.19,20 Therefore, it is not surprising that many cancer 
treatments result in both short- and long-term side effects, which may manifest as accelerated 
aging, with older adults at particular risk.21–24 
There is emerging data suggesting that cancer therapy may be associated with an 
accelerated aging phenotype. These data come primarily from the pediatric literature, where 
pediatric cancer survivors are noted to have an increase in chronic conditions (second malignancies, 
congestive heart failure, myocardial infarction) and frailty.11,12,25  In older adults, the accelerated 
aging phenotype manifests as an increased number of comorbidities,26 increased mobility limitations 
and limitations in activities in daily living,27 poorer mental and physical health-related quality of 
life,28,29 and declines in neuropsychological function.24 Objective measures of physiological health 
further support the development of an accelerated aging phenotype among patients receiving 
systemic cancer therapy (chemotherapy/endocrine therapy) demonstrated by a decline in exercise 
capacity as measured by VO2peak
30–32 and a maximal cycle ergometer test.33   
At a molecular or cellular level, the impact of cancer or cancer therapy on the patient is still 
a relatively unexplored area, as most cancer research is focused on the impact of the therapy on the 
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associated with aging.34,35 Studies in humans demonstrate that a potential biomarker of aging, 
p16ink4a expression measured in peripheral blood T cells, is increased among patients who receive 
adjuvant chemotherapy for breast cancer. The rise in p16ink4a expression is 0.81 log2 order of 
magnitude (corresponding to a 14.7 year increase in chronological age) immediately after treatment, 
with the impact sustained 12 months after treatment.35 VEGF-A and MCP1 (senescence-associated 
cytokines) also increase with chemotherapy, while no change in telomere length was noted.35 Other 
studies, however, have shown that chemotherapy affects telomere length36 and is associated with 
telomere shortening in peripheral blood mononuclear cells,37 as well as in hematopoietic stem 
cells.38 The oldest patients may be at greater risk, as telomere shortening was shown to be greater in 
older patients given combined chemotherapy and radiation for head and neck cancer when 
compared with younger patients.39 
Furthermore, there is a complex relationship between aging, cancer, cancer therapeutics, 
cellular senescence, and inflammation. Aging itself is associated with a chronic low grade 
inflammation (“inflammaging”), which may contribute to the development of chronic diseases, 
including cancer.40 Furthermore, cancer in and of itself may lead to immune activation and systemic 
inflammation, which can induce damage both locally as well as at a distance.41,42 Cancer therapeutics 
induce cellular senescence and the development of a senescence-associated secretory phenotype 
(SASP), which is associated with the secretion of growth factors, proinflammatory cytokines, and 
proteases.43,44 Together, this can create a tissue microenvironment that may promote the 
development of cancer and other chronic diseases, as well as accelerate the aging process.45 
One potential alternative of treating cancer that may not accelerate the aging process––or 
at least lessen it––is cancer immunotherapy. After the exciting breakthrough with checkpoint 
inhibitors––anti-PD-L1 and anti-CTLA4 antibodies––in patients with melanoma, lung cancer, 
leukemia, and kidney cancer,46 cancer immunotherapy has been considered as one of the most 
promising therapies to treat metastatic cancer.  Cancer immunotherapy is less harsh than 
chemotherapy or radiation. Although cancer immunotherapy is less likely than chemotherapy to 
accelerate aging, the long-term effects of cancer immunotherapy on aging needs to be studied. 
However, cancer immunotherapy is less effective at old than young ages, due to T cell 
unresponsiveness caused by various age-related changes in the immune system. This includes lack of 
naive T cells, defects in activation pathways of T cells and antigen-presenting cells (APCs), and age-
related changes in the tumor microenvironment.47–50 Most cancer therapies are developed in young 
animals, including cancer immunotherapies. Since immunotherapy is recognized as a potentially 
important treatment for cancer in the near future, and since most cancer patients are old, analyzing 
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cancer immunotherapy to a higher level. Chemotherapeutics induce a proinflammatory cytokine–
driven milieu in the tumor microenvironment that leads to accelerated aging. Examples are the 
production of interleukin 6 (IL-6) and transforming growth factor β (TGF-β), both produced by 
tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in the tumor 
microenvironment.51 However, several chemotherapeutics eliminate TAMs and MDSCs and thus 
reduce the production of these proinflammatory cytokines in the tumor microenvironment.51–54 
These cytokines also strongly induce immune suppression and T cell unresponsiveness.  
Genomic instability is a hallmark of aging, and this leads to loss of antigens and escape of 
tumor cells from the immune system. Developing therapies that induce immunogenic tumor cell 
death, combined with immune adjuvants, will lead to the presentation of all antigens expressed by 
the patients’ own tumors to the immune system.55 If one antigen is lost through genomic instability, 
there is always another antigen present on the tumor cells that can be recognized by T cells. While 
this type of immunotherapy may prevent the escape of tumor cells from the immune system, it does 
not prevent or delay genomic instability. Finally, more targeted therapies with less side effects on 
normal tissues is an important alternative to prevent or delay accelerated aging. To analyze whether 
these alternative therapies indeed have a reduced potential to induce accelerated aging, they need 
to be studied over the long term. Such studies need to be carefully designed in aging animals to 
determine the potential of accelerated aging at various time points in life and to separate the 
complex relationships among aging, cancer, cancer therapeutics, cellular senescence, and 
inflammation. 
There are many unanswered questions regarding cancer, cancer therapeutics, and 
accelerated aging. First, research is needed to further elucidate the biologic basis of how cancer or 
cancer therapies directly affect the pillars of aging. Second, how much of this damage is due to the 
tumor itself versus the specific therapies? Third, what is the trajectory of accelerated aging from 
cancer and cancer therapies, who is most at risk, and is there a specific tipping point that places a 
host at increased vulnerability? Fourth, how do we prevent or reverse an accelerated aging 
trajectory? Oncology is a perfect model to study these questions. There are few other examples in 
medicine where a significant stressor (such as chemotherapy) is applied that unmasks the 
individual’s biologic reserve, placing them at risk for accelerated aging. The stressor is then 
withdrawn, allowing for potential reversal (resilience) from the biologic insult. A deeper 
understanding of the biologic basis underlying this clinically common phenomenon would inform our 
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When used optimally, antiretroviral therapy suppresses HIV replication indefinitely. Although 
durable suppression of the virus essentially eliminates the risk of developing AIDS-related 
complications and prolongs life, it does not fully restore health. For reasons that are the focus of 
extensive investigation, antiretroviral drug–treated adults are more likely to acquire an aged clinical 
phenotype faster than age-matched adults living without HIV. This is true regardless of how one 
defines the aged phenotype––by disease accumulation, functional decline, impaired physical and 
cognitive function, multimorbidity, development of geriatric syndromes, or self-reported quality of 
life.  
Rates of chronic illnesses––hypertension, diabetes, cardiovascular disease, 
osteoporosis/bone fractures, chronic obstructive pulmonary disease, kidney disease, liver disease, 
and many cancers––are approximately 1.5- to 2-fold higher in HIV-infected compared with 
uninfected adults.56–58 For example, in one cohort study, 30–35% of subjects aged 50–65 have two or 
more comorbid conditions (in addition to HIV), compared with approximately 10% in that age range 
for HIV-uninfected adults.58  
Perhaps the most compelling evidence suggesting that HIV affects healthy aging comes from 
a series of observations indicating that frailty (or frailty-like syndromes) and other geriatric 
syndromes are more prevalent among those with HIV. Indeed, the rates reported for those with HIV 
between 50 and 55 years are comparable to those in the 70+ year range in the general population. 
This is true even after controlling for many potential confounders, including drug use, other 
exposures, psychosocial factors, socioeconomic status, and other key variables.59  In a recent study 
of men 50 and older in San Francisco,60 prefrailty (56%), difficulty with instrumental activities of daily 
living (46%), and cognitive impairment (47%) were the most common geriatric syndromes, and risk 
factors were lower for nadir CD4 count, non-white race, and increasing number of comorbidities.   
These cross-sectional data have led the popular press and the community to the concern 
that HIV somehow accelerates aging. Longitudinal data to support this concept are limited, however. 
Among men with and without HIV followed in the MACS cohort, gait speeds in HIV-infected and 
uninfected adults were comparable at about age 50 years, but thereafter, the rate of decline in 
normal walking speed is increased in HIV-infected versus uninfected adults. The median age at which 
walking speed falls below 1m/s was 57 years in those with HIV compared with 66 years in those 
without HIV.61 
HIV-associated neurologic dysfunction (including dementia) was widespread and devastating 
as a consequence of HIV in the pretreatment era. The neurologic syndromes that persist or emerge 
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neurocognitive disorder” (HAND). Several factors likely contribute to this syndrome, including 
irreversible damage produced by HIV before treatment (HIV infects many cells within the CNS), 
antiretroviral toxicity, HIV-associated inflammation, and the presence of other comorbidities.62,63     
Self-reported health impairments in domains noted with advancing age are increased in 
those with HIV: psychosocial stress, fatigue, and poor perception of health.  Major depressive 
disorders and comorbid medical conditions, lower reported premorbid functioning, neurocognitive 
impairment, and nadir CD4 count are the strongest predictors of poor self-reported health and 
functional status.64,65   
Important overarching issues in HIV/aging research.  
HIV associated immune dysfunction. Infection with HIV is a dynamic event. Viral replication is 
overwhelming during the first few weeks of infection, with viral copies in the peripheral blood that 
approach 108 to 109/mL. HIV replication during this time causes rapid depletion of tissue-based CD4+ 
T cells (the primary target for the virus), high level inflammation, and tissue fibrosis. Ongoing harm 
from HIV replication persists until ART is started, at which time the immune system begins to slowly 
recover. This treatment-associated recovery is often incomplete, however. Lymphoid tissue fibrosis 
persists indefinitely. Subtle immunodeficiency is common, even as one’s peripheral CD4+ T cell 
counts are normalized. Inflammation within the innate and adaptive immune system remains 
elevated. Biomarkers associated with persistent activation of monocytes/macrophages (e.g., IL-6, 
sCD14) and the adaptive immune system (e.g., the CD4/CD8 ratio) typically persist during ART and 
are consistently associated with progression to all-cause morbidity. Collectively, this persistent 
immunologic dysfunction predicts and presumably contributes to a higher risk of a number of 
diseases common in older people, including cardiovascular disease, cancer, liver and kidney 
dysfunction, neurologic decline, and infectious complications, such as zoster. 
Antiretroviral drug toxicity. Antiretroviral therapy is now indicated for essentially everyone 
living with HIV, even those living in resource-poor areas of the world. The effectiveness of these 
drugs in preventing AIDS, prolonging life, and reducing transmission is no longer questioned. Still, 
these drugs are not benign, and all may have subtle toxicities that could prevent healthy aging. All 
reverse transcriptase inhibitors impair mitochondrial replication, but the effect varies by the specific 
drug, so exposure to one generation of drug is very different than another (e.g., stavudine versus 
tenofovir vary by nearly 1000-fold with regard to mitochondrial DNA polymerase inhibition). 
Individual drugs also have toxicities that may be important; for example, tenofovir has bone and 
kidney-related side effects that are unique, while many protease inhibitors lead to hyperlipidemia 
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the efficacy of those additional drugs commonly used in older individuals. Polypharmacy is a 
common predictor of poor health outcomes in the general population and will almost certainly 
prove to be a major factor in healthy aging in those with HIV. 
Cohort effects.  Treatment strategies have evolved dramatically over the past 25 years. 
During the early treatment era, antiretroviral drugs were often toxic and generally not used until 
people had more advance disease. The treatments being used today are initiated as early as possible 
and are generally much safer. Accordingly, HIV cohorts from the 1980s are very different than those 
from the 1990s and the 2000s. As an example, a 70-year-old HIV-infected adult in 2016 who was 
infected in 1982 and diagnosed in 1988 is likely to have been exposed to multiple antiretroviral 
drugs with poorly controlled viral replication. In fact, he/she would be a survivor from a cohort 
where the vast majority did not survive and hence more likely to be resilient than those in the 
broader population. In contrast, a 70-year old who acquired the infection in 1998 and was diagnosed 
in 2005 is likely to have been treated with well-tolerated ART at an earlier stage of infection. 
Potential confounders. Acquisition of HIV is associated with many risk behaviors, and those 
factors may differentially influence aging. (e.g., IV drug use, cancer-causing coinfections such as 
human papilloma virus (HPV) or hepatitis B/C.) Further, other risk factors (e.g., cigarette smoking, 
isolation from family/social support) do not increase the risk of HIV acquisition, but because they are 
more prevalent in HIV+ subjects, it is critical to control such factors through appropriate study 
design. 
Common pathways of aging: synergies with HIV infection.  
Aging biology and geroscience. Substantial progress in our understanding of the basic 
biology of aging and of geroscience has allowed the definition of a few hallmarks or pillars that 
appear to drive the process.7,8,10  In the next few paragraphs, we will consider how each of these 
pillars is affected by HIV infection and/or ART.  
Inflammation and senescence. As in aging, ongoing, low-level inflammation is a hallmark of 
chronic HIV infection, even for those receiving ART, and inflammation is a risk factor for 
cardiovascular disease, HAND, geriatric syndromes, and other aspects of the aged 
phenotype.56,58,66,67 The source of this inflammation is not certain, but three primary areas of focus 
are discussed below.  
Though typically suppressed below measured levels in the blood by ART, HIV production, 
and perhaps replication, is not completely eradicated by treatment. Several anatomic compartments 
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reservoirs may be a source of inflammation, and, through a vicious cycle, inflammation is a trigger to 
low-level HIV production and replication. The importance of low-level viral replication in causing 
non-AIDS morbidity is perhaps best demonstrated by recent studies of reduced hospitalization and 
cardiovascular event rates by ART in those rare untreated individuals who have no detectable 
viremia (the so-called “elite controllers”).69 
HIV leads to massive T cell turnover and immune exhaustion, contracted naive T cell 
populations, and expanded memory T cell populations (especially those T cells directed toward other 
chronic viruses, like CMV). This occurs at a younger age than in those without HIV70 and is only 
partially mitigated by ART.71   It has been known for many years that aging results in a similar 
phenotype, characterized by accumulation of more terminally differentiated CD8+ T cells in 
peripheral blood. T cell activation––perhaps due to reservoirs of HIV replication––appears to be 
critical to the accumulation of these T cells.72 Dysfunctional T cells with an inflammatory phenotype 
(which are often referred to as “senescent”) accumulate in response to a number of chronic viral 
infections, including CMV and HIV. These cells have short telomeres, poor telomerase activity, and 
typically secrete high levels of inflammatory cytokines. These senescent cells in and of themselves 
may cause age-related disease, such as osteoarthritis.73 Elimination of senescent cells via senolytics–
–drugs that are able to push senescent cells to apoptosis––may have profound antiaging effects.74  
After the initial HIV infection, gut lymphoid tissue is decimated and recovery after ART is 
incomplete,75 leading to increased translocation of microbes and microbial products that incite 
inflammation. Altered gut immune response is also associated with changes in the gut microbiome 
that may play a role in HIV-related inflammation.76,77 A large number of studies are now examining 
ways to modulate the microbiome and microbial translocation through probiotics and other 
interventions. The gut microbiome also has profound effects on liver metabolic pathways and may 
be of major importance in the metabolic changes noted below. 
Epigenetics. DNA methylation is a good marker of biologic (versus chronologic) age and is 
associated with physical and cognitive function.78 HIV infection leads to methylation at many of the 
same, and some unique, sites as noted with aging, and HIV accelerates the rate of age-related DNA 
methylation changes in multiple cell types.79,80 Depending on the study, this acceleration is on the 
order of 5–14 years in peripheral blood mononuclear cells and is true in different age cohorts (ages 
20–24 and ages 48–56). These data suggest that the initial HIV “hit” may be most responsible for this 
change, rather that prolonged exposure to HIV and/or ART, and that there is little or no cohort effect 
in this phenomenon.80 There is a strong correlation between advanced DNA methylation and the 
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methylation patterns that are 5–7 years more advanced than expected for the chronological age of 
the individual.81  
Stress response. Maladaptation of the stress response is apparent in people with chronic or 
overwhelming stress and may be relevant in HIV infection.82 Resilience is the capacity to 
appropriately respond and recover from stress and is linked to both the perception of an event as 
stressful and the biologic changes that respond to and appropriately terminate a stress response. 
Many HIV-associated factors could conceivably affect resilience, including socioeconomic factors 
(poor social support systems, poverty), depression, substance use, polypharmacy, and persistent 
end-organ damage (e.g., neuropathy, myopathy, mild cognitive impairment, vascular disease, and 
the metabolic syndrome). Social isolation may be a particularly relevant contributor to poor 
resilience in HIV-infected older adults owing to inadequate social support and the stigma of having 
HIV infection, which itself may be perceived as a stress. Finally, there are also data suggesting that 
HIV proteins themselves may influence the stress response.83       
Metabolism. HIV and its treatment are associated with marked changes in metabolism, 
particularly of glucose and fatty acids,84 and glucose intolerance and frank diabetes mellitus are 
frequent. Some of this is very likely related to ART side effects. The well-described lipodystrophy 
syndrome that resulted after ART in the 1990s and early 2000s is much less common with newer 
drugs, but marked changes in body composition/weight gain, particularly in the period shortly after 
starting ART, are common and confer much of the diabetes mellitus risk.85  This is particularly true in 
those already overweight at the time of ART initiation.86  In addition, metabolic changes in lipid and 
glucose metabolism are commonly associated with many antiretroviral drugs.87  Liver disease, 
predominantly fatty liver, is also very common in those living with HIV.88   
Macromolecular damage. HIV and ART have major effects on mitochondrial health and 
replication.89  As noted previously, the effect on mitochondrial DNA polymerase varies greatly by 
individual drugs even within a class, but once mitochondrial deletion mutations or other 
macromolecular changes occur they can be propagated throughout the life span of the cell, leading 
to impaired stress responses, poor resilience, early senescence, and metabolic derangements. 
Telomerase activity is impaired by HIV, common co-infections (e.g., CMV) and ART.90  These effects 
and increased rates of cell turnover result in premature telomere shortening in those with HIV, 
particularly in T cells.91  Telomerase also has profound effects on mitochondrial health that may play 
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Proteostasis. HIV also has marked effects on autophagy and other proteostatic networks 
within and between cells.93,94   These effects are propagated by specific, HIV-encoded protein 
products (nef and env), but may differentially affect specific cell types.93     
In summary, studying the interactions between HIV and aging requires careful attention to the 
biology of the virus and its impact on immunity, as well as potential confounders, such as ART, 
cohort effects, and common risk factors for disease (e.g., cigarette smoking, social isolation). The 
interaction of HIV biology with the biology of aging is likely to shed light on both HIV and 
geroscience, and HIV+ subjects are an excellent population in which to consider antiaging 
interventions to assess their effect on the development of the aged phenotype.      
Diabetes 
Type 2 diabetes, by far the most common type in older adults, is an age-related disease. The 
prevalence of diabetes is 33% among people in the United States aged 65 years or older, and in 
addition nearly 50% of older people meet criteria for prediabetes. 95 The incidence of newly 
diagnosed diabetes is the highest among those aged 65–79 years. Older adults with diabetes 
mellitus are susceptible to all the usual complications of diabetes (reviewed in Ref. 96).  Rates of 
end-stage renal disease, loss of vision, myocardial infarction,97 stroke, peripheral vascular disease, 
and peripheral neuropathy all increase with age in the absence of diabetes. However, the presence 
of diabetes greatly increases the risk for these health problems in older adults (summarized in Ref. 
98), a clear basis for viewing diabetes as a driver of age-related diseases.  
On the other hand, generalizations need to be examined in detail, since some features of 
diabetes that appear to resemble accelerated aging in fact have important pathophysiological 
differences from aging; some features of diabetes do not appear to accelerate aging. For example, 
some severe microvascular complications of diabetes, such as proliferative retinopathy and end-
stage nephropathy (Kimmelstein-Wilson lesions), are pathologically distinct from eye and kidney 
changes with age in the absence of diabetes. Another relevant example is insulin resistance, which 
contributes to hyperglycemia in human type 2 diabetes. However, insulin resistance is also an 
adaptive/protective response, and animal models of insulin resistance often live significantly 
longer.99 Conversely, numerous models with enhanced insulin sensitivity live normal or shorter life 
spans. The intersection between insulin resistance and aging may not be relevant to accelerated 
aging in diabetes, although impaired insulin secretion in diabetes may share common mechanisms 
with aging.  
The pathophysiology of type 2 diabetes is unknown, but it appears to occur as a result of a 
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central feature of this model is a decline of βcell function and insulin secretion with aging, 
consistently observed in rodents and humans.100 Aging effects include a decline of both pancreatic 
islet βcell proliferation and β cell turnover.101,102 One example is the inability of old mice to increase 
islet mass and βcell proliferation in response to a high-fat diet, as is observed in young mice.103 
Exposure to high concentrations of glucose in vitro can lead to apoptosis of β cells, evidence of 
glucose toxicity,100 to which older rodents are more susceptible.101 
Pancreatic islet β cell proliferation appears to be dependent on cell cycle regulation.  There 
is a substantial increase in expression of the cell cycle regulator p16 in islet tissue from older mice 
who demonstrate the age-related decline in islet proliferation.  Overexpression of p16 markedly 
reduces islet proliferation in younger mice to a level similar to that observed in older mice, and 
knockout of p16, preventing p16 from increasing with aging, appears to reverse the age-related 
decline of islet cell proliferation in this model.104 Furthermore, p16 is one of the proteins produced 
from the CDKN2a locus. Genetic variation at this locus has emerged as a consistent association with 
type 2 diabetes risk from genome-wide scanning studies in humans.105–108   
Findings from humans parallel age-related changes observed in rodents, including 
diminished insulin secretion in vitro and in vivo, diminished proliferative capacity, and increased 
sensitivity to the apoptotic effects of high glucose exposure.100,109 In the setting of the age-related 
impairment of β cell function, there is a maladaptive response to lifestyle-related insulin resistance, 
leading to more impaired insulin secretion and progression to impaired glucose tolerance 
(prediabetes) and type 2 diabetes.110 Glucose toxicity from chronic exposure to hyperglycemia, in 
turn, can contribute directly to insulin resistance and to further impairment of pancreatic β cell 
function. In this way, hyperglycemia of diabetes may drive further worsening of β cell function and 
proliferation associated with aging.  
Diabetes links directly to the seven pillars of aging: epigenetics, inflammation/senescence, 
proteostasis, stem cells, metabolism, stress response, and macromolecular damage. Thus, diabetes 
may augment/enhance the pillars of aging, leading to premature or accelerated appearance of 
multiple age-specific conditions.   
Hyperglycemia in diabetes is a disturbance of metabolism that alters proteins 
(,acromolecular damage) and proteostasis by creating advanced glycation end products (AGEs), 
which increase oxidative stress, leading to activation of kinases and increased production of 
proinflammatory mediators.111 These pathways also deplete endothelial and neural nitric oxide, 
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Type 2 diabetes increases the risk for both vascular dementia and Alzheimer’s disease.96.112–
114 Diabetes is also associated with an increased risk of mild cognitive impairment (MCI)115 and an 
increased rate of conversion from MCI to dementia.116 Diabetes and Alzheimer’s disease pathology 
can exert synergistic effects with age on the brain vasculature, blood flow, and delivery of substrates 
necessary for cognition.117 Hyperglycemia increases production of AGEs and their receptors in the 
brain, and both type 2 diabetes and Alzheimer’s disease can reduce brain cholesterol synthesis. 
People with diabetes may have brain areas of glucose hypometabolism, gray matter atrophy, and 
reduced blood flow in a pattern similar to that seen with Alzheimer’s disease.117,118 Both peripheral 
insulin resistance and brain insulin resistance have been hypothesized to play important roles in 
neurocognitive dysfunction and dementia.119 For example, mice with knockout of the insulin 
receptor in the brain show increased tau phosphorylation. Postmortem brain tissue has shown the 
presence of some biochemical features reminiscent of insulin resistance in the hippocampal 
formation of persons with AD compared with normal controls, and this insulin resistance is 
associated with pathology that involves both Aβ oligomers and fibrillar amyloid plaques.  
There are notable age-associated changes in specific aspects of cardiac structure and 
cardiovascular function. Diabetes also has a major impact on the heart120,121 and can accelerate the 
changes with aging. For example, diabetes can dramatically worsen age-related changes in diastolic 
dysfunction.120,121  
Similarly, there are substantial interactions of aging and diabetes on blood vessels. 
Inflammation and oxidative stress associated with aging and diabetes appear to play synergistic roles 
in the vasculature. Aging arteries exhibit a chronic inflammatory profile resulting from increased 
superoxide availability similar to that seen with diabetes, leading to intrinsic cell stiffness in the 
vascular smooth muscle and endothelial dysfunction.122,123 There may also be an important role for 
adult stem cells located in perivascular areas in the endothelial dysfunction.  
Increased leukocyte trafficking in response to hyperglycemia and insulin resistance has been 
linked with damage to blood vessels and surrounding tissue in diabetes, owing to the production of 
toxic mediators by activated leukocytes.124–127 In addition, an inflammatory response characterized 
by enhanced endothelial adhesiveness and increased leukocyte–endothelium interactions occurs in 
the microvasculature during metabolic disorders such as diabetes. Loss of physiologic endothelial 
nitric oxide (eNO) appears to be an important mechanism for this vascular inflammation,127–129 which 
is likely to be a key contributing factor to accelerated aging. More work is needed to understand the 
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Another example of how diabetes may drive age-related deterioration is in the kidney. Older age is a 
risk factor for end-stage kidney disease, the most common cause of which is diabetes. Conversely, diabetes 
induces kidney cell senescence independent of age.130 Diabetes is associated with increased oxidative stress 
in the kidney that is augmented by aging.131 In both diabetes and aging, monocyte infiltration is commonly 
seen in the kidney. Kidney cell nuclear localization of NF-κB, a master regulator of cytokine expression, is 
increased in aging rodents.132 An inflammatory response appears to contribute to the demise of type 2 
diabetic mice. Infusion of early endothelial outgrowth cells seems to improve senescence, induce autophagy, 
and ameliorate kidney injury in diabetic mice,133 and infusion of bone marrow cells from young mice 
ameliorates senescent changes in the kidney in old mice.134 Thus, stem cells may play a role in protecting 
against kidney damage in aging diabetic mice. In addition, DNA damage occurs in the kidney in diabetes and 
aging. Epigenetic acetylation markers are increased within genes related to inflammation in peripheral blood 
monocytes from diabetic patients with renal and retinal damage.135   
Finally, the glucose-lowering drugs metformin136 and acarbose137 both extend life span in animal 
models. While the mechanism by which they do it is not clear, these findings suggest a significant overlap 
between the molecular underpinnings of diabetes and those of aging. Further studies on how these drugs 
interact with each of these processes will likely shed further light on the complex interrelations between 
type 2 diabetes mellitus and aging. 
Discussion  
The summit provided ample time for in-depth discussion of many aspects of the interrelations 
between disease and aging. Necessarily, not all these elements have been included in this summary. 
However, several major overarching points became clear during these discussions. First and 
foremost, it has become apparent that, while geroscience offers a window into the mechanistic 
overlap between aging and chronic disease, the initial focus on aging being the main risk factor for 
disease needs to be revisited in at least two ways. First, as exemplified by the title of the summit, the 
relationship is a two-way street: not only is aging the major risk factor for disease, but diseases 
might also be major risk factors for accelerating physiological aging phenotypes. Second, the 
geroscience hypothesis should expand to encompass aging physiology as well as chronic disease, 
resulting in a greater emphasis on health in general. 
Several groups have recently identified a finite number of major pillars that are either known or 
suspected of driving the aging process.9,10 As the discussions in New York City indicate, many of 
these pillars are directly or indirectly affected by exposure to chronic diseases and/or their 
treatments. As a result, it is reasonable to suspect that these pillars are involved in the development 
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experiencing those diseases. As such, it becomes clear that the physiological impact of diseases (as 
well as treatments against them), such as cancer, HIV, diabetes and many others can result in an 
acceleration of the phenotypes associated with natural aging. Among those phenotypes, an 
increased susceptibility to additional major chronic diseases is paramount. In this sense, the 
geroscience hypothesis closes the loop between aging and chronic disease, suggesting that 
interventions designed to slow the rate of aging may ameliorate the long-term outcome of chronic 
diseases and their therapeutic management. This may be particularly the case when those diseases 
affect individuals at an earlier age. Of course, many questions remain. 
 A deeper understanding is still needed about the basic biology of each disease and of aging. 
While it is often argued that an understanding of the basic biology is not necessarily a sine 
que non for development of effective interventions, it is clear that a further understanding 
of both disease and aging at the molecular and cellular levels will help us better develop 
comprehensive approaches to treating chronic diseases.  
 A further examination of the role of aging and disease in defining the “genes  environment 
= phenotype” equation for each disease’s susceptibility is also a need. It is interesting to 
consider that, while aging increases susceptibility to most such diseases, individuals vary in 
this regard based on each individual’s specific genes and environmental context, which leads 
to the development of different diseases in each individual. In this regard, early exposure to 
a particular disease might cause a preferential exacerbation of one or more pillar of aging, 
and, as such, the susceptibility later in life might be skewed towards diseases that depend 
more heavily on those pillars that were affected. This should be an area to investigate in 
further detail via detailed epidemiological and clinical approaches.  
 Do these diseases change the rate of aging or the starting set-point? As discussed earlier, it 
has been suggested that, at least in the case of HIV/AIDS, infection with the virus leads to an 
immediate resetting of at least some parameters that define aging, apparently with little or 
no effect on the later trajectory of the parameter. It is currently unknown whether a similar 
situation occurs in additional parameters or in other diseases. For example, it is known that 
cancer chemo- and radiotherapies lead to a rapid accumulation of senescent cells. Many of 
these are cleared over time by the immune system, but there are residual cells not cleared 
that could have effects on tissue physiology later in life, including the possibility of 
senescence-driven senescence in neighboring cells. This in turn could increase susceptibility 
to diseases that depend heavily on cell senescence, such as diabetes, osteoarthritis, 
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 Early exposure to disease should be considered as a possible confounder in studies of 
interventions that may slow the rate of aging. Because these early exposures might activate 
some individual aging pillars more than others, it is important to consider that 
responsiveness to any given intervention will then be dependent on early exposures. On the 
brighter side, a further understanding of these interrelationships should facilitate 
personalized interventions geared to the needs of each individual. 
In closing, there is an important consideration that begs for focused research: should age-
retarding interventions be administered in conjunction with disease-fighting therapies? As has been 
discussed, all therapies are expected to leave sequelae, and these are likely to affect the individual’s 
susceptibility to additional diseases later in life. This is particularly relevant in cases such as cancer, 
where the traditional armamentarium focuses on trying to destroy a cell that, other than its 
unbridled capacity for proliferation, very much resembles other dividing cells in the body. The 
secondary effects of these therapies have long been recognized as being close to unacceptable. As 
major strides are being made to identify interventions that address the aging process directly, it 
becomes a burning question to consider whether any such interventions would be advisable in 
patients suffering from diseases known or suspected to lead to accelerated aging. Would it be 
advisable, for example, to provide senolytics (as defined above, and after proper vetting of their 
modes of actions and secondary effects) to cancer patients concomitantly or immediately following 
chemo- or radiotherapy? 
The shared physiological end result of natural aging and disease-accelerated aging provide yet 
another opportunity for cross-disciplinary collaborations, one of the goals of the organizers of the 
summit, the trans-NIH GeroScience Interest Group. Recognizing that health encompasses more than 
absence of disease, a concerted effort in this area should provide benefits for disease patients and 
the elderly alike, further advancing the goal of biomedicine: to provide health to the entire spectrum 
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